Al- Anbar Medical Journal

Pulse Pressure Index as a Discriminator of Predicting the Cardiovascular Events in Hypertensive Patients Treated with Drugs Acting on Angiotensinogen-Angiotensin Pathway

Document Type : Original articles

Authors

1 College of Medicine, Al-Mustansiriya University, Baghdad, Iraq

2 Department of pharmacology, College of Medicine, University of Anbar, Ramadi, Anbar, Iraq

Abstract

Background: Pulse pressure index as a function of pulse pressure divided by systolic blood pressure served is a useful predictor of cardiovascular events.
Objectives: Our aim was to assess the pulse pressure index as a discriminating variable of predicting cardiovascular events in untreated or hypertensive patients and treated with one member of angiotensin converting enzyme inhibitors or angiotensin receptor blockers by using the scores of Framingham study.
Materials and methods: This observational cross-sectional study, including 140 patients who grouped into; Group I (n = 30): untreated hypertensive patients; Group II (n = 60): patients treated with angiotensin receptor blockers; and Group III (n = 50): patients treated with angiotensin converting enzyme inhibitors. Anthropometric measurements, lipid profile, and blood pressure were determined. The probability of ten-year of cardiovascular events was calculated according to the Framingham study scores using The University of Edinburgh Cardiovascular Risk Calculator (http://cvrisk.mvm.ed.ac.uk/calculator/calc.asp).
 Results: There is a non-significant difference between Groups and within Groups of age, smoking habit, and the values of the cardio metabolic risk factors. Pulse pressure index as an independent risk factor found to be a significant discriminator of 10-year prediction of cardiovascular events by using the receiving operating characteristic curves.
Conclusion: The pulse pressure index is a useful discriminator of predicting cardiovascular events, and it will improve the Framingham prediction risk among hypertensive patients.   

Keywords

Main Subjects

References
[1] A. Chugh and G. L. Bakris. Pulse pressure and arterial stiffness: an emerging renal risk predictor? J. Hypertens, 25:1796–1797, 2017.
[2] Y. Peng-Lin and L. Yue-Chun. Pulse pressure index (pulse pressure/systolic pressure) may be better than pulse pressure for assessment of cardiovascular outcomes. Med. Hypotheses, 72(6):729–731, 2009.
[3] C. Borghi et al. Zofenopril and ramipril in combina[1]tion with acetyl salicylic acid in postmyocardial infarc[1]tion patients with left ventricular systolic dysfunction: A retrospective analysis of the smile-4 randomized , double[1]blind study in diabetic patients. Cardiovascular Thera[1]peutics, 34(2):76–84, 2016.
[4] A. Awada. Primary and secondary prevention of ischemic stroke. J. Med. Liban., 59(4):213–219, 2011.
[5] A. Muthuraman P. Kaur and M. Kaur. The implications of angiotensin-converting enzymes and their modulators in neurodegenerative disorders: current and future per[1]spectives. ACS Chem. Neurosci., 6(4):508–521, 2015.
[6] S. G. Vijan. Angiotensin-converting enzyme inhibitors (aceis), not angiotensin receptor blockers (arbs), are pre[1]ferred and effective mode of therapy in high cardiovascu[1]lar risk patients. J. Indian Med. Assoc., 107(3):178–182, 2009.
[7] L. Akioyamen et al. Cardiovascular and cerebrovascu[1]lar outcomes of long-term angiotensin receptor blockade: meta-analyses of trials in essential hypertension. J. Am. Soc. Hypertens., 10(1):55–69, 2016.
[8] C. Keller and J. Mueller-Ehmsen. Pharmacological pri[1]mary prevention of myocardial infarction, stroke and death: A possible task? Dtsch. Med. Wochenschr., 141(18):1330–1332, 2016.
[9] S. Foulquier et al. Impact of telmisartan on cardiovas[1]cular outcome in hypertensive patients at high risk: a telmisartan randomised assessment study in ace intoler[1]ant subjects with cardiovascular disease subanalysis. J. Hypertens., 32(6):1334–1341, 2014.
[10] M. Ashwell and S. Gibson. Waist-to-height ratio as an in[1]dicator of early health risk: simpler and more predictive than using a matrixbased on bmi and waist circumfer[1]ence. BMJ Open, 32(6), e010159, 2016.
[11] K. M. Hanus et al. Relationship between gender and clin[1]ical characteristics, associated factors, and hypertension treatment in patients with resistant hypertension. Kar[1]diol. Pol. (Polish Hear. Journal), 75(5):421–431, 2017.
 [12] P. Lokaj, J. Parenica, M. P. Goldbergova, K. Helenova, R. Miklik, P. Kubena, and et al. Pulse pressure in clinical practice. Eur. J. Cardiovasc. Med., 2(1):66–68, 2011.
[13] V. Vaccarino, T. R. Holford, and H. M. Krumholz. Pulse pressure and risk for myocardial infarction and heart fail[1]ure in the elderly. J. Am. Coll. Cardiol., 36(1):130–138, 2000.
 [14] K. Okada, H. Iso, R. Cui, M. Inoue, and S. Tsugane. Pulse pressure is an independent risk factor for stroke among middle-aged japanese with normal systolic blood pressure the jphc study. J. Hypertens., 29(2):319–324, 2011.
[15] L. Potier et al. Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in high vascular risk. Heart, 103(17):1339–1346, 2017.
 [16] K. Miura et al. Pulse pressure compared with other blood pressure indexes in the prediction of 25-year cardiovas[1]cular and all-cause mortality rates: The chicago heart association detection project in industry study. Hyper[1]tension, 38(2):232–237, 2001.
 [17] T. S. Nawrot et al. Should pulse pressure become part of the framingham risk score?J. Hum. Hypertens., 18(4):279–286, 2004
Al- Anbar Medical Journal
Volume 15, Issue 1
June 2019
Page 1-5
Files
Share
Export Citation
Statistics